Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 257808, 8 pages
http://dx.doi.org/10.1155/2012/257808
Clinical Study

Evaluation of Serum Adipokines in Peripheral Arterial Occlusive Disease

Surgical Clinic II, “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca, No. 4-6 Clinicilor Street, 400006 Cluj-Napoca, Romania

Received 12 October 2011; Revised 6 January 2012; Accepted 20 January 2012

Academic Editor: Oreste Gualillo

Copyright © 2012 Claudia D. Gherman and Aurel I. Mironiuc. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The World Health Organization (WHO), “Reducing Risks, Promoting Healthy Life,” The World Health Report, World Health Organisation, 2002, http://www.who.int/whr/2002/en.
  2. P. Calabrò, E. Golia, V. Maddaloni et al., “Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?” Internal and Emergency Medicine, vol. 4, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Maury and S. M. Brichard, “Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome,” Molecular and Cellular Endocrinology, vol. 314, no. 1, pp. 1–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Mathieu, P. Pibarot, and J. P. Després, “Metabolic syndrome: the danger signal in atherosclerosis,” Vascular Health and Risk Management, vol. 2, no. 3, pp. 285–302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. T. J. Guzik, D. Mangalat, and R. Korbut, “Adipocytokines—novel link between inflammation and vascular function?” Journal of Physiology and Pharmacology, vol. 57, no. 4, pp. 505–528, 2006. View at Google Scholar · View at Scopus
  6. A. H. Berg and P. E. Scherer, “Adipose tissue, inflammation, and cardiovascular disease,” Circulation Research, vol. 96, no. 9, pp. 939–949, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, and H. Löwel, “Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men. Results from the 18-year follow-up of a large cohort from Southern Germany,” Journal of the American College of Cardiology, vol. 48, no. 7, pp. 1369–1377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. U. C. Broedl, C. Lebherz, M. Lehrke et al., “Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques,” PLoS ONE, vol. 4, no. 3, Article ID e4733, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kumada, S. Kihara, S. Sumitsuji et al., “Association of hypoadiponectinemia with coronary artery disease in men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 85–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader, “Resistin is an inflammatory marker of atherosclerosis in humans,” Circulation, vol. 111, no. 7, pp. 932–939, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Kawanami, K. Maemura, N. Takeda et al., “Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions,” Biochemical and Biophysical Research Communications, vol. 314, no. 2, pp. 415–419, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Anfossi, I. Russo, G. Doronzo, A. Pomero, and M. Trovati, “Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells,” Mediators of Inflammation, vol. 2010, Article ID 174341, 26 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M.-L. Delporte, S. A. El Mkadem, M. Quisquater, and S. M. Brichard, “Leptin treatment markedly increased plasma adiponectin but barely decreased plasma resistin of ob/ob mice,” American Journal of Physiology, vol. 287, no. 3 50-3, pp. E446–E453, 2004. View at Publisher · View at Google Scholar
  14. F. Lago, R. Gómez, J. J. Gómez-Reino, C. Dieguez, and O. Gualillo, “Adipokines as novel modulators of lipid metabolism,” Trends in Biochemical Sciences, vol. 34, no. 10, pp. 500–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Gualillo, J. R. González-Juanatey, and F. Lago, “The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives,” Trends in Cardiovascular Medicine, vol. 17, no. 8, pp. 275–283, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. B. G. Windham, M. E. Griswold, S. M. Farasat et al., “Influence of leptin, adiponectin, and resistin on the association between abdominal adiposity and arterial stiffness,” American Journal of Hypertension, vol. 23, no. 5, pp. 501–507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. D. Hooi, A. D. M. Kester, H. E. J. H. Stoffers, P. E. L. M. Rinkens, J. A. Knottnerus, and J. W. Van Ree, “Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study,” Journal of Clinical Epidemiology, vol. 57, no. 3, pp. 294–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. Murabito, M. J. Keyes, C. Y. Guo et al., “Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the Framingham offspring study,” Atherosclerosis, vol. 203, no. 2, pp. 509–514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. H. Wild, C. D. Byrne, I. Tzoulaki et al., “Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: the Edinburgh artery study,” Atherosclerosis, vol. 203, no. 2, pp. 604–609, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Dieplinger, W. Poelz, M. Haltmayer, and T. Mueller, “Association of adiponectin and amino terminal proBNP in peripheral arterial disease,” Clinica Chimica Acta, vol. 377, no. 1-2, pp. 192–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Dieplinger, W. Poelz, M. Haltmayer, and T. Mueller, “Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 7, pp. 830–833, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. “Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, pp. 3143–3421, 2002.
  23. G. Eknoyan, “Adolphe Quetelet (1796–1874)—the average man and indices of obesity,” Nephrology Dialysis Transplantation, vol. 23, no. 1, pp. 47–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Wood, R. Wray, N. Poulter et al., “JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice,” Heart, vol. 91, no. 5, supplement, pp. 1–52, 2005. View at Publisher · View at Google Scholar
  25. D. S. Frankel, R. S. Vasan, R. B. D'Agostino et al., “Resistin, adiponectin, and risk of heart failure. The Framingham offspring study,” Journal of the American College of Cardiology, vol. 53, no. 9, pp. 754–762, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Kahn, “Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, vol. 20, no. 7, pp. 1183–1197, 1997. View at Google Scholar · View at Scopus
  27. L. Jäntschi and S. D. Bolboacǎ, “Exact probabilities and confidence limits for binomial samples: applied to the difference between two proportions,” TheScientificWorldJOURNAL, vol. 10, pp. 865–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D. Bolboacă and L. Jäntschi, “Optimized confidence intervals for binomial distributed samples,” International Journal of Pure and Applied Mathematics, vol. 47, no. 1, pp. 1–8, 2008. View at Google Scholar
  29. T. Colton, Statistics in Medicine, Little Brown and Company, New York, NY, USA, 1974.
  30. S. Stenholm, E. J. Metter, G. S. Roth et al., “Relationship between plasma ghrelin, insulin, leptin, interleukin 6, adiponectin, testosterone and longevity in the Baltimore Longitudinal Study of Aging,” Aging, vol. 23, no. 2, pp. 153–158, 2011. View at Google Scholar
  31. F. Marra and C. Bertolani, “Adipokines in liver diseases,” Hepatology, vol. 50, no. 3, pp. 957–969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Ouriel, “Peripheral arterial disease,” Lancet, vol. 358, no. 9289, pp. 1257–1264, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Krȩcki, J. Drozdz, P. Szcześniak, D. Orszulak-Michalak, and M. Krzemińska-Pakuła, “Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease,” Kardiologia Polska, vol. 66, no. 11, pp. 1173–1180, 2008. View at Google Scholar · View at Scopus
  34. B. Kopff and A. Jegier, “Adipokines: adiponectin, leptin, resistin and coronary heart disease risk,” Przegląd lekarski, vol. 62, pp. 69–72, 2005. View at Google Scholar · View at Scopus
  35. W. Erb, “Klinische beiträge zur pathologie des intermittieren den hinkens,” Münchener Medizinische Wochenschrift, vol. 2, p. 2487, 1911. View at Google Scholar
  36. I. Smith, P. J. Franks, R. M. Greenhalgh, N. R. Poulter, and J. T. Powell, “The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia,” European Journal of Vascular and Endovascular Surgery, vol. 11, no. 4, pp. 402–408, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. B. R. Zimmerman and P. J. Palumbo, “A prospective study of peripheral occlusive arterial disease in diabetes—III. Initial lipid and lipoprotein findings,” Mayo Clinic Proceedings, vol. 56, no. 4, pp. 233–242, 1981. View at Google Scholar
  38. K. C. B. Tan, A. Xu, W. S. Chow et al., “Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 765–769, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Hou and J.-D. Luo, “Leptin and cardiovascular diseases,” Clinical and Experimental Pharmacology and Physiology, vol. 38, no. 12, pp. 905–913, 2011. View at Publisher · View at Google Scholar
  40. H. S. Elbatarny, S. J. Netherton, J. D. Ovens, A. V. Ferguson, and D. H. Maurice, “Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases,” European Journal of Pharmacology, vol. 558, no. 1–3, pp. 7–13, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Napoleone, A. Di Santo, C. Amore et al., “Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk?” Journal of Thrombosis and Haemostasis, vol. 5, no. 7, pp. 1462–1468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Recasens, W. Ricart, and J. M. Fernández-Real, “Obesity and inflammation,” Revista de medicina de la Universidad de Navarra, vol. 48, no. 2, pp. 49–54, 2004. View at Google Scholar · View at Scopus
  43. G. S. Hotamisligil, “Mechanisms of TNF-α-induced insulin resistance,” Experimental and Clinical Endocrinology and Diabetes, vol. 107, no. 2, pp. 119–125, 1999. View at Google Scholar · View at Scopus
  44. M. Fasshauer, J. Klein, S. Neumann, M. Eszlinger, and R. Paschke, “Tumor necrosis factor α is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 288, no. 4, pp. 1027–1031, 2001. View at Publisher · View at Google Scholar
  45. N. Ouchi, S. Kihara, Y. Arita et al., “Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway,” Circulation, vol. 102, no. 11, pp. 1296–1301, 2000. View at Google Scholar · View at Scopus
  46. T. Yamauchi, J. Kamon, H. Waki et al., “Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis,” Journal of Biological Chemistry, vol. 278, no. 4, pp. 2461–2468, 2003. View at Publisher · View at Google Scholar · View at Scopus